Development and use of alefacept to treat psoriasis (Q35190096)

7 August 2017

1 reference

title

Development and use of alefacept to treat psoriasis (English)

1 reference

7 August 2017

Gerald G Krueger

1

1 reference

PubMed ID

12894131

7 August 2017

Kristina P Callis

series ordinal

2

1 reference

PubMed ID

12894131

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Journal of the American Academy of Dermatology

7 August 2017

1 reference

7 August 2017

49

1 reference

7 August 2017

S87-97

1 reference

7 August 2017

2 Suppl

1 reference

Treatment of psoriasis. Part 2. Systemic therapies

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.552

Treatment of psoriasis. Part 1. Topical therapy and phototherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.552

Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.552

The pathogenesis of psoriasis: immunological facts and speculations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.552

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.552

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.552

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.552

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.552

Severe Psoriasis – Oral Therapy with a New Retinoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.552

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/MJD.2003.552

1 reference

7 August 2017

1 reference

PubMed ID

12894131